Amicus Therapeutics Shares Fall Hard After The Bell Print E-mail
By Staff and Wire Reports   
Thursday, 20 December 2012 03:59
icon_studyresultsAmicus shares closed the regular trading session at $5.77 on Wednesday on the Nasdaq, but fell as low as $2.80 after the bell. This following an announcement that Amicus Therapeutics' (FOLD) experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended trade on Wednesday.

The company is developing migalastat HCl in partnership with British drugmaker GlaxoSmithKline plc (GSK.L) to treat Fabry disease, a genetic condition in which a type of fat gets deposited in human tissue, particularly in the kidneys. The disease is caused by the body's inability to produce the enzyme that helps breaks down the fat.

The six-month study found that 13 out of the 32 patients who were put on migalastat HCl reported a reduction of 50 percent or more in the fat deposits in their kidneys, compared to 9 of the 32 in the group that was given a placebo.

"This difference did not achieve statistical significance according to the pre-specified primary endpoint analysis," the company said.

Amicus said it expects to report results from 12 months of treatment in the first half of 2013, after which it plans to meet with the FDA to discuss a U.S. "approval pathway."

John F. Crowley, Chairman and Chief Executive Officer of Amicus, stated "Consistent with our Phase 2 experience, the 6-month results from Study 011 demonstrate notable trends in kidney interstitial capillary GL-3 reduction in favor of migalastat HCl monotherapy compared to placebo. We look forward to announcing additional 6-month results at the WORLD Symposium in February, including a presentation of important secondary and tertiary endpoints in this study. We also anticipate 12-month results from this study in the first half of 2013. Once we have the 12-month data, we intend to meet with FDA to discuss a U.S. approval pathway. We continue to believe that migalastat HCl may become an important treatment option as an oral monotherapy drug for both men and women with Fabry disease who have amenable mutations."



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter